<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509210</url>
  </required_header>
  <id_info>
    <org_study_id>VX06-950-012</org_study_id>
    <nct_id>NCT00509210</nct_id>
  </id_info>
  <brief_title>Study of Telaprevir in Subjects With Hepatic Impairment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir
      following administration of multiple oral doses to subjects with moderate and severe hepatic
      impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
  </primary_outcome>
  <condition>Hepatic Insufficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telaprevir (VX-950)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed with Child Pugh score of 7-9 or greater than 10

          -  Women of non-childbearing age

        Exclusion Criteria:

          -  Tested positive for HIV, Hepatitis C, Hepatitis B
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Y Kwo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University, Department of Medicine, Division of Gastroenterology/Hepatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University, Department of Medicine,Division of Gastroenterology / Hepatology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <lastchanged_date>October 28, 2008</lastchanged_date>
  <firstreceived_date>July 30, 2007</firstreceived_date>
  <keyword>Liver Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
